Search Prime Grants

U01DA043809

Cooperative Agreement

Overview

Grant Description
Genetic control of addiction by host and microbiome.
Funding Goals
TO SUPPORT BASIC AND CLINICAL NEUROSCIENCE, BIOMEDICAL, BEHAVIORAL AND SOCIAL SCIENCE, EPIDEMIOLOGIC, HEALTH SERVICES AND HEALTH DISPARITY RESEARCH. TO DEVELOP NEW KNOWLEDGE AND APPROACHES RELATED TO THE PREVENTION, DIAGNOSIS, TREATMENT, ETIOLOGY, AND CONSEQUENCES OF DRUG ABUSE AND ADDICTION, INCLUDING HIV/AIDS. TO SUPPORT RESEARCH TRAINING AND RESEARCH SCIENTIST DEVELOPMENT. TO SUPPORT DISSEMINATION OF RESEARCH FINDINGS. SMALL BUSINESS INNOVATION RESEARCH (SBIR) LEGISLATION IS INTENDED TO EXPAND AND IMPROVE THE SBIR PROGRAMS TO EMPHASIZE AND INCREASE PRIVATE SECTOR COMMERCIALIZATION OF TECHNOLOGY DEVELOPED THROUGH FEDERAL SBIR RESEARCH AND DEVELOPMENT, INCREASE SMALL BUSINESS PARTICIPATION IN FEDERAL RESEARCH AND DEVELOPMENT, AND FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN THE SBIR PROGRAM. THE LEGISLATION INTENDS THAT THE SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM STIMULATE AND FOSTER SCIENTIFIC AND TECHNOLOGICAL INNOVATION THROUGH COOPERATIVE RESEARCH AND DEVELOPMENT CARRIED OUT BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, FOSTER TECHNOLOGY TRANSFER BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, AND FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION.
Place of Performance
Connecticut United States
Geographic Scope
State-Wide
Analysis Notes
Amendment Since initial award the End Date has been extended from 07/31/23 to 07/31/24 and the total obligations have increased 388% from $812,782 to $3,967,474.
Jackson Laboratory was awarded Genetic Control of Addiction by Host and Microbiome Cooperative Agreement U01DA043809 worth $3,967,474 from National Institute on Drug Abuse in September 2018 with work to be completed primarily in Connecticut United States. The grant has a duration of 5 years 10 months and was awarded through assistance program 93.279 Drug Abuse and Addiction Research Programs. The Cooperative Agreement was awarded through grant opportunity Identification of Genetic and Genomic Variants by Next-Gen in Sequencing Non-human Animal Models (U01) .

Status
(Complete)

Last Modified 12/5/24

Period of Performance
9/30/18
Start Date
7/31/24
End Date
100% Complete

Funding Split
$4.0M
Federal Obligation
$0.0
Non-Federal Obligation
$4.0M
Total Obligated
100.0% Federal Funding
0.0% Non-Federal Funding

Activity Timeline

Interactive chart of timeline of amendments to U01DA043809

Subgrant Awards

Disclosed subgrants for U01DA043809

Transaction History

Modifications to U01DA043809

Additional Detail

Award ID FAIN
U01DA043809
SAI Number
U01DA043809-2345289442
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Nonprofit With 501(c)(3) IRS Status (Other Than An Institution Of Higher Education)
Awarding Office
75N600 NIH NATIONAL INSITUTE ON DRUG ABUSE
Funding Office
75N600 NIH NATIONAL INSITUTE ON DRUG ABUSE
Awardee UEI
XR6LMXNKDJJ1
Awardee CAGE
9N885
Performance District
CT-90
Senators
Richard Blumenthal
Christopher Murphy

Budget Funding

Federal Account Budget Subfunction Object Class Total Percentage
National Institute on Drug Abuse, National Institutes of Health, Health and Human Services (075-0893) Health research and training Grants, subsidies, and contributions (41.0) $4,824,358 100%
Modified: 12/5/24